Session » (1592–1611) Vasculitis – ANCA-Associated Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1609

A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis

10:30AM-12:30PM: Abstract Number: 1607

Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort

10:30AM-12:30PM: Abstract Number: 1602

Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1605

Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

10:30AM-12:30PM: Abstract Number: 1593

Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients

10:30AM-12:30PM: Abstract Number: 1599

Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses

10:30AM-12:30PM: Abstract Number: 1610

Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients

10:30AM-12:30PM: Abstract Number: 1597

Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 1611

Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study

10:30AM-12:30PM: Abstract Number: 1608

Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1596

GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency

10:30AM-12:30PM: Abstract Number: 1604

Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study

10:30AM-12:30PM: Abstract Number: 1592

Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

10:30AM-12:30PM: Abstract Number: 1601

Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series

10:30AM-12:30PM: Abstract Number: 1606

One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System

10:30AM-12:30PM: Abstract Number: 1600

Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study

10:30AM-12:30PM: Abstract Number: 1603

SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement

10:30AM-12:30PM: Abstract Number: 1595

Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1594

Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis

10:30AM-12:30PM: Abstract Number: 1598

Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study

« View all sessions from this meeting